Rosetta Genomics Announces Publication Of Study On MicroRNA Expression For Lung Tumor Classification
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung tumors and metastases to the lung...
(more...)
(more...)